Stock Report: TearLab Corp. (TEAR) Report Updated: May 20, 2013 | Print This Page

TearLab Corporation operates as an ophthalmic device company. It engages in developing and commercializing TearLab Osmolarity System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease. The company’s system enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, which is a single-use microfluidic microchip; TearLab pen, which is a hand-held device that interfaces with the TearLab disposable; and TearLab reader, which is a small desktop unit that allows for the docking of the TearLab disposable and the TearLab pen, as well as provides a quantitative reading for the operator. TearLab Corporation markets its system through a network of distributors in North America, Europe, and Asia. The company, formerly known as OccuLogix, Inc., was founded in 1996 and is headquartered in San Diego, California.